ReviewEndocrine2016
Non-functioning pituitary adenomas: growth and aggressiveness.
Review in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Management of Recurrent and Aggressive Non-Functioning Pituitary Adenomas.Journal of clinical medicine · 2025Review
- A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors.International journal of molecular sciences · 2025Review
- Neurological and Systemic Pitfalls in the Diagnosis of Cluster Headaches: A Case-Based Review.Current neurology and neuroscience reports · 2024Review
- Sleep and cognition in South African patients with non-functioning pituitary adenomas.PloS one · 2024Article
- Comparing redo surgery and stereotactic radiosurgery for recurrent, residual, and/or tumors showing progression in nonfunctioning pituitary adenomas: A systematic review and meta-analysis.Surgical neurology international · 2024Review
- Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section.Acta neurochirurgica · 2021Review
- Article
- Is pituitary MRI screening necessary in cluster headache?Cephalalgia : an international journal of headache · 2021Article
- Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features.Journal of clinical medicine · 2020Article
- Article
- Clinical and Pathological Aspects of Silent Pituitary Adenomas.The Journal of clinical endocrinology and metabolism · 2019Review
- Article
- Review
- Histopathological classification of non-functioning pituitary neuroendocrine tumors.Pituitary · 2018Review
- Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas.Endocrine · 2017Article
- DoIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenomas (PAs) are common, comprising approximately one third of all intracranial tumors. Non-functioning pituitary adenomas (NFPAs) are the most common PAs. Although usually benign, the NFPAs represent therapeutic challenges because of their location close to the optic chiasm and nerves, and the proximity to the pituitary gland. The therapeutic alternatives are surgery and radiation. To date there is no effective medical treatment. NFPAs are classified according to different modalities, but there are no reliable marker of aggressiveness to guide the clinician in monitoring the patient. More information on growth patterns with constituent biological markers are needed to tailor the care of this patient group. Studies characterizing the membrane receptors of NFPAs have shown promising results, which may give rise to the development of medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.